Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
Date:8/2/2009

DETROIT, Aug. 3 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announces today that it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol(R).

Under the settlement agreement, MedImmune grants Caraco a license to certain patents, permitting Caraco to continue marketing a generic version of Ethyol(R) in the United States. The settlement resolves the entirety of the litigations between the parties.

The terms of the settlement are confidential.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for ne
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
4. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
5. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
6. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
7. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... to extremely low levels with a combination drug appears ... patients with clogged arteries, a new study found. ... Vytorin, a drug that combines a cholesterol-lowering statin called ... investigator Dr. Christopher Cannon, a cardiologist at Brigham and ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... patients can safely take aspirin combined with a blood-thinning medication, ... a patient,s risk of early death, according to a new ... Heart Association in Chicago. The report was also published online ... data from more than a dozen clinical trials revealed no ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
... Sudden cardiac,arrest is a leading cause of death ... condition, it is imperative that every school develop ... they need to respond,effectively to children and adults ... perform CPR and use an automated external defibrillator,(AED) ...
... Jones addressed the issue of health disparities during a,Ways ... part are,as follows., "Mr. Chairman, I am appreciative ... disparities as we continue to move forward with,health reform ... not just to my district, but to,districts across the ...
... on the Impact of ... Technology in Healthcare, PLANO, Texas, June 10 ... President, International Healthcare Guest: ... Humana, Perot Systems continues its series of ...
... drug approved for osteoporosis prevention and treatment has provided ... a breast cancer preventative for certain cancers. Women ... develop invasive, estrogen-receptor (ER) positive breast cancer compared with ... results of the randomized controlled trial will be published ...
... , , TUESDAY, June 10 (HealthDay News) -- Regardless of the ... women, and smoking increases any adult,s risk of death just ... according to new risk of death charts. , The charts, ... the Journal of the National Cancer Institute show ...
... Maine, June 10 Sen. Olympia Snowe,(R-ME), member ... Medicare,bill -- S.3101 -- that includes pharmacy-related provisions ... drug claims and delay the,implementation of Medicaid reimbursement ... RPh, owner of Waltz Pharmacy Inc. in,Camden, ME ...
Cached Medicine News:Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Tubbs Jones Addresses Health Disparities Issue During Hearing 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 3Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 2Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 3Health News:Researchers Update Risk-of-Death Charts 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
(Date:11/18/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Monday, December 8, 2014 at 9:00 a.m. Eastern Time to ... th American Society of Hematology Annual Meeting and Exposition.  ... by dialing 877-443-5662 or access the webcast at www.isispharm.com ... time at the same address. ABOUT ISIS ...
(Date:11/18/2014)... 18, 2014  Renova Therapeutics, a biopharmaceutical company ... and other chronic diseases, announced that Daniel ... The company also completed its third round of ... board member brings decades of life science experience ... executive with more than 30 years of experience ...
(Date:11/17/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye, today announced ... Medical Technology & Diagnostics Forum in New ... Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ET. ... of the Company,s current business trends, financial results, and ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 2Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 3STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish....
... designed with thinner, long jaws to ... through a tunnel or clear corneal ... lens securely, but will not damage ... enough to allow the lens to ...
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Medicine Products: